A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

被引：0
|
作者：
Rosenberg, Jonathan
Sabatier, Renaud
Viceneux, Armelle
Rouge, Thibault De la Motte
Champiat, Stephane
Lebellec, Loic
Barthelemy, Philippe
Sonpavde, Guru
Gao, Xin
Niglio, Scot
Zhang, Tian
Gedye, Craig
Galsky, Matthew
Milowsky, Matthew
Reimers, Melissa
Weickhardt, Andrew
Grande, Enrique
Castellano, Daniel E.
Bilen, Mehmet
Patnaik, Amita
Zerbib, Robert
Balbas, Minna
Xu, Xiaojian
Aptaker, Kaitlyn
Balar, Arjun V.
Awada, Ahmad H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT084
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
    Demetri, George D.
    Luke, Jason J.
    Hollebecque, Antoine
    Powderly, John D.
    Spira, Alexander I.
    Subbiah, Vivek
    Lai, Dominic W.
    Yue, Huibin
    Kasichayanula, Sreeneeranj
    Gulbranson, Scott
    Purcell, James
    Myzak, Melinda
    Robinson, Randy
    Villalobos, Victor Manuel
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
    Lopez, Diana M.
    Barve, Minal
    Wang, Judy
    Bullock, Andrea J.
    Pectasides, Eirini
    Vaishampayan, Ulka
    Spira, Alexander I.
    Ulahannan, Susanna
    Patnaik, Amita
    Sanborn, Rachel E.
    Cicic, Dragan
    Ang, Qiuqing
    Bergonio, Gregory
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [23] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
    Call, Justin
    Orr, Douglas
    Anderson, Ian
    Richardson, Debra L.
    Chen, Zhu
    Ma, Sharon
    Hunder, Naomi N.
    Hamilton, Erika
    CANCER RESEARCH, 2023, 83 (08)
  • [24] Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
    Call, Justin A.
    Orr, Douglas W.
    Anderson, Ian Churchill
    Richardson, Debra L.
    Chen, Zhu
    Ma, Sharon
    Hunder, Naomi N. H.
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
    Lemech, Charlotte
    Woodward, Natasha
    Chan, Nancy
    Mortimer, Joanne
    Naumovski, Louie
    Nuthalapati, Silpa
    Tong, Bo
    Jiang, Fang
    Ansell, Peter
    Ratajczak, Christine K.
    Sachdev, Jasgit
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
  • [26] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
    Charlotte Lemech
    Natasha Woodward
    Nancy Chan
    Joanne Mortimer
    Louie Naumovski
    Silpa Nuthalapati
    Bo Tong
    Fang Jiang
    Peter Ansell
    Christine K. Ratajczak
    Jasgit Sachdev
    Investigational New Drugs, 2020, 38 : 1815 - 1825
  • [27] First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
    Tsimberidou, Apostolia Maria
    Vo, Henry Hiep
    Beck, Jennifer
    Shia, Chi-Sheng
    Hsu, Pei
    Pearce, Tillman E.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [28] Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
    Forero, A.
    Burris, H., III
    Mita, M.
    Specht, J.
    Weise, A.
    Liu, M. C.
    Modi, S.
    Pusztai, L.
    Kostic, A.
    Yang, J.
    Li, M.
    Hengel, S.
    Miller, K.
    CANCER RESEARCH, 2016, 76
  • [29] A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors.
    Jiang, Lijuan
    Song, Zhengbo
    Gong, Yi
    Jin, Jianan
    Ding, Yao
    Tang, Long
    Deng, Xia
    Li, Xiangdong
    Li, Su
    Cheng, Xiangdong
    Zhou, Fangjian
    Zhou, Xiaoyan
    Fu, Ziyi
    Yu, Jin-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] First-in-human study of OBI-999: A globo H-targeting antibody-drug conjugate in patients with advanced solid tumors
    Tsimberidou, Apostolia Maria
    Hsu, Pei
    Pearce, Tillman E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345